Payment, Coverage, and Health Economics of SGLT2 Inhibitors

Kidney360. 2021 Mar 18;2(6):1031-1035. doi: 10.34067/KID.0000742021. eCollection 2021 Jun 24.

Authors

Ngoc-Yen T Pham¹, Christos P Argyropoulos², Sireesha Koppula²

Affiliations

¹ Pharmacy Department, University of New Mexico Hospitals, Albuquerque, New Mexico.
² Department of Internal Medicine, Division of Nephrology, University of New Mexico School of Medicine, Albuquerque, New Mexico.

No abstract available

Keywords: chronic kidney disease; coverage; diabetic kidney disease; health economics; sodium glucose cotransporter two inhibitors.

MeSH terms

Diabetic Nephropathies*
Humans
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors